Lab
State of Rhode Island
State of Rhode Island was paid $6.43M by Medicaid between Jan 2018 and Nov 2024, across 10 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 30% of everything it billed.
33Billing provider infoSTATE OF RHODE ISLAND
PROVIDENCE, RI 02904
PROVIDENCE, RI 02904
33aNPI1174690887assigned 11/29/2006
33bProvider typeClinical Medical Laboratory
28Total paid$6.43M
24GClaims304,470
24DCodes billed10
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Rhode Island
Rank by total paid#3 of 6
Median peer was paid$1.49M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 60,048 | $1.31M | |
| 2019 | 48,224 | $990K | |
| 2020 | 27,420 | $580K | |
| 2021 | 46,158 | $1.03M | |
| 2022 | 43,710 | $966K | |
| 2023 | 43,962 | $860K | |
| 2024incomplete | 34,948 | $683K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 30% | 70,591 | 63,409 | $1.93M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 29% | 69,619 | 62,656 | $1.88M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 13% | 47,888 | 43,545 | $846K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 8.0% | 20,314 | 19,631 | $514K |
| 83655 | 7.3% | 48,897 | 44,658 | $472K | |
| 86780 | 5.8% | 37,237 | 34,023 | $373K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 4.4% | 4,936 | 3,925 | $285K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.9% | 3,753 | 2,530 | $122K |
| 86592 | <1% | 1,026 | 922 | $3K | |
| 86803 | <1% | 209 | 206 | $2K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGALLAGHER, GLEN (LAB DIRECTOR)